Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

ope.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment ahead of schedule for TB-402. We believe that based on its novel profile, TB-402 could be an important new entrant into the anticoagulant therapy market. Given the size of commercial opportunity for TB-402 and the sales reach that will be needed to engage with all of the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent. We very much look forward to announcing the results from this study in Q2 next year."

Svein Mathisen, CEO of BioInvent, also commented, "At BioInvent, we are proud to have maintained excellent momentum in the Phase II study of TB-402, which is on track to be completed ahead of schedule. We look forward to announcing the results of the study in Q2 next year. Our expectation is that the ongoing clinical development will underpin the product profile as a safe and effective long acting new anticoagulant."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 600,000 patients are treated for venous thromboembolisms such as DVT or pulmonary embolism (PE) each year.[1] Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.[2]

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.[3] Patients undergoing hip replacement or knee surgery are particularly at risk of developing DVT and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. The annual sales of anticoagulants
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, has recently released a ... is a topical liquid tetracycline-based antibiotic that uses ... convert oral medication active ingredients into topical drugs. ... aid antibiotic to help prevent skin infection in ...
(Date:10/30/2014)... 30, 2014 CVS Health (NYSE: CVS ... with three leading regional health systems to enhance access to ... systems include Baptist Health System in Alabama ... Health in Pennsylvania , Northwest Medical Center, ... and Tennova Healthcare in Tennessee ; and ...
(Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
(Date:10/30/2014)... Five months after their expansion, the ... new branding and a website to accompany their recent ... Mepham’s promotion to name partner earlier this year, Hodgkinson ... Mepham’s name and better reflect their combined litigation expertise. ... decision to implement new branding reflects Hodgkinson Street Mepham’s ...
(Date:10/30/2014)... CT (PRWEB) October 30, 2014 Radio ... are raising questions about the impact of traditional radio ... marketing method most likely to influence a purchasing decision. ... poll of 525 consumers conducted by radio marketing company ... product categories, isolating the results of respondents who indicated ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... 30, 2014 Horse Sense & ... riding to special needs individuals in the Jacksonville area, ... November 15 from 10-2:00 p.m. at Bailey's Farm (2202 ... to the public and is designed to raise awareness ... to the HSS Round-Up is free. Ticket purchases will ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... MONICA, Calif., Feb. 3 The most common New ... on,physical appearance: lose weight, tone up, exercise more, and ... finding an intimate relationship,between body and mind. In order ... to maintain mental health and cognitive function as well ...
... 3 The US market for the drug treatment of ... to US Cancer Pain, a report released today by WWMR, ... a trend expected to continue throughout the next decade. ... primary driver of market value during the forecast period. ...
... CDC reports decline in two-thirds of the country, , , TUESDAY, ... decade in nearly two-thirds of the states, according to a ... Prevention. , The CDC,s data analysis showed that mammography use ... including Minnesota, Tennessee, Georgia and Alabama. But it fell by ...
... play a critical role in world,s largest global ... coming months, hundreds of Rotary club members from ... the United Kingdom and the Caribbean will join ... and health workers to immunize children against polio ...
... Breakthrough findings contribute to better understanding of little-known disease ... Feb. 3 A new research study has identified ... primary torsion dystonia (DYT6 type) in Amish-Mennonite families and ... that THAP1 causes dystonia in other ethnic groups.A paper ...
... Texas, Feb. 3 UpSpring Baby (TM) today ... breast milk is now available for purchase over-the-counter at ... is the nation,s largest drugstore chain and the first ... test. Milkscreen is also available for purchase through ...
Cached Medicine News:Health News:Dakim Recommends Six New Year Resolutions to Stay Cognitively Fit 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 3Health News:Fewer Women Are Having Mammograms 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 3Health News:The Bachmann-Strauss Dystonia & Parkinson Foundation: New Study Identifies Gene Mutations as Cause of Dystonia in Amish-Mennonite Families 2Health News:Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens 2
... Dynal RELI™ SSO typing technique utilises a ... flank the specific target region of an ... of the resulting amplicon to an array ... a nylon membrane. The immobilisation of these ...
... The Reichert UNISTAT ... photometric analyzer for determining ... newborn infants. It quickly ... tests are needed by ...
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
... Follicle-Stimulating Hormone (FSH) is a glygoprotein produced by ... as LH, TSH, and HCG, FSH consists of ... is a solid phase direct sandwich ELISA method. ... to the wells coated with Mab to FSH ...
Medicine Products: